The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat

Table 6

Tissue-specific rates of FFA incorporation into storage 𝑅_𝑓𝑠 (µmol/100 g/min).

Group	Lean		Obese		Tesaglitazar
State	Basal	ClampL	Basal	ClampL	Basal	ClampL
Red gastroc	0.68±0.10^∗∗	0.32±0.02	1.81±0.44	2.19±0.25	1.68±0.30	0.41±0.02^‡‡
White fat	0.84±0.20	0.13±0.03	1.15±0.14	1.15±0.22	1.90±0.25^∗∗	0.32±0.05^‡‡‡
Heart	4.7±0.5^∗∗∗	4.6±0.5	12.3±1.6	15.3±1.4	4.8±0.3^∗∗∗	4.9±0.3
Cerebellum	0.32±0.02^∗∗∗	0.09±0.01	0.64±0.09	0.58±0.11	0.52±0.05	0.09±0.01^‡‡
Liver	24.8±1.0^∗∗∗	5.4±0.5	37.7±3.9	31.1±3.4^†	45.7±4.1^∗	7.2±0.9^‡‡‡

Results are mean ± SE (𝑛 = 6–8). Groups of animals were studied either in the basal state or during isoglycemic clamps performed at physiological levels of hyperinsulinemia suited to each group (insulin infusion rates as for ClampL in Study 2, defined in Table 3). Red gastroc abbreviation for red gastrocnemius. Basal state differences; ^∗𝑃<0.05, ^∗∗𝑃<0.01, and ^∗∗∗𝑃<0.001 versus obese. Response to insulin (ClampL-Basal) differences; ^†𝑃<0.05 Obese versus Lean and ^‡‡𝑃<0.01, ^‡‡‡𝑃<0.001 Tesaglitazar versus Obese.